ENANTA PHARMACEUTICALS INC
ENTANASDAQ🏆 #2911 by market capEarnings Nov 16US Equity
$13.48▼ $0.04 (−0.32%)
Live1h▼ 0.4%
24h▼ 0.3%
7d▲ 2.0%
14d▲ 8.3%
30d▼ 1.6%
1y▲ 96.7%
🏦Market Cap
$392M
Small Cap
📈Revenue Growth (YoY)
-3.4%
Declining
📊Gross Margin
98.2%
High
💵FCF Margin
-56.6%
Thin
⚖️P/S Ratio
6.0x
Fair
Otter Score
55
Weak
📊
Analyst Ratings
Price
$13.48
Total
19
Raised
1
Lowered
0
Avg PT
$20.00
H / L
$20 / $20
| Institution | Action | Rating | Date |
|---|---|---|---|
HC Wainwright & Co. | Reiterated | Buy | 2026-06-23 |
Jefferies | Upgraded | Hold → Buy | 2025-10-01 |
WestPark Capital | Reiterated | Buy | 2025-09-30 |
Evercore ISI Group | Reiterated | Outperform | 2025-09-15 |
JMP Securities | Reiterated | Market Outperform | 2025-08-12 |
Baird | Reiterated | Outperform | 2024-11-26 |
JP Morgan | Reiterated | Underweight | 2024-08-06 |
Oppenheimer | Reiterated | Perform | 2023-11-22 |
RBC Capital | Reiterated | Sector Perform | 2023-10-02 |
SVB Leerink | Reiterated | Market Perform → Perform | 2023-02-09 |
Piper Sandler | Reiterated | Overweight | 2023-02-08 |
Roth Capital | Reiterated | Buy | 2022-05-12 |
Berenberg | Reiterated | Buy | 2018-12-13 |
Barclays | Reiterated | Underweight | 2016-02-09 |
Leerink Swann | Reiterated | Outperform | 2015-05-08 |
Deutsche Bank | Reiterated | Buy | 2015-04-06 |
FBR Capital | Reiterated | Outperform | 2014-10-21 |
Macquarie | Reiterated | Outperform | 2014-06-17 |
Credit Suisse | Reiterated | Outperform | 2013-04-15 |
One row per institution, most recent rating